Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: A modelling study
This is my archive
Current Capacity for Diagnosing Alzheimer’s Disease in Germany and Implications for Wait Times
Considerations for widespread implementation of blood‐based biomarkers of Alzheimer’s disease
Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer’s disease
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatmentsImplications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration.
State Department of Motor Vehicles Reporting Mandates of Dementia Diagnoses and Dementia Underdiagnosis
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States
Estimated Investment Need to Increase England’s Capacity to Diagnose Eligibility for an Alzheimer’s Treatment to G7 Average Capacity Levels
